VaxInnate Corporation's Novel Recombinant Flu Vaccine Named a Top 10 Biopharma Project to Watch in 2011  
11/1/2010 11:29:43 AM

CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation announced today that VAX125, its investigational prototype vaccine for seasonal flu, has been named one of the Top 10 Infectious Diseases Projects to Watch in 2011 by Elsevier Business Intelligence and the Windhover Conferences.